98%
921
2 minutes
20
Background: This study aimed to develop a radiogenomic prognostic prediction model for colorectal cancer (CRC) by investigating the biological and clinical relevance of intratumoural heterogeneity.
Methods: This retrospective multi-cohort study was conducted in three steps. First, we identified genomic subclones using unsupervised deconvolution analysis. Second, we established radiogenomic signatures to link radiomic features with prognostic subclone compositions in an independent radiogenomic dataset containing matched imaging and gene expression data. Finally, the prognostic value of the identified radiogenomic signatures was validated using two testing datasets containing imaging and survival information collected from separate medical centres.
Results: This multi-institutional retrospective study included 1601 patients (714 females and 887 males; mean age, 65 years ± 14 [standard deviation]) with CRC from 5 datasets. Molecular heterogeneity was identified using unsupervised deconvolution analysis of gene expression data. The relative prevalence of the two subclones associated with cell cycle and extracellular matrix pathways identified patients with significantly different survival outcomes. A radiogenomic signature-based predictive model significantly stratified patients into high- and low-risk groups with disparate disease-free survival (HR = 1.74, P = 0.003). Radiogenomic signatures were revealed as an independent predictive factor for CRC by multivariable analysis (HR = 1.59, 95% CI:1.03-2.45, P = 0.034). Functional analysis demonstrated that the 11 radiogenomic signatures were predominantly associated with extracellular matrix and immune-related pathways.
Conclusions: The identified radiogenomic signatures might be a surrogate for genomic signatures and could complement the current prognostic strategies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730572 | PMC |
http://dx.doi.org/10.1186/s12967-022-03788-8 | DOI Listing |
Front Oncol
August 2025
Department of Imaging, Yantaishan Hospital, Yantai, Shangdong, China.
This systematic review evaluates the integration of radiomics, artificial intelligence (AI), and molecular signatures for diagnosing and prognosticating bone and soft tissue tumors (BSTTs). Following PRISMA 2020 guidelines, we analyzed 24 studies from 1,141 initial records across PubMed, Scopus, Web of Science, and Google Scholar. Our findings reveal that while radiomics-AI pipelines are well-developed for BSTT assessment - particularly using MRI (72% of studies) and CT (25%) with machine learning classifiers like random forests (42%) and CNNs (17%) - molecular data integration remains virtually absent.
View Article and Find Full Text PDFCancer Med
September 2025
Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, China.
Background: Oncotype DX 21-gene assays are recommended for evaluating distant recurrence and guiding decisions on the use of adjuvant therapy in ER+/HER2- breast cancers. However, it cannot be widely applied due to the high cost and time consumption.
Purpose: To identify MRI radiomics signatures within tumor and peritumoral tissues associated with the 21-gene recurrence score (RS) and explore their value in predicting 5-year recurrence in young women with ER+/HER2- breast cancer.
Radiol Med
August 2025
Department of Radiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Recent advances in molecular genetics have revolutionized the classification of pediatric-type high-grade gliomas in the 2021 World Health Organization central nervous system tumor classification. This narrative review synthesizes current evidence on the following four tumor types: diffuse midline glioma, H3 K27-altered; diffuse hemispheric glioma, H3 G34-mutant; diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype; and infant-type hemispheric glioma. We conducted a comprehensive literature search for articles published through January 2025.
View Article and Find Full Text PDFElife
August 2025
Molecular and Experimental Surgery, Clinic for General-, Visceral -, Vascular- and Transplantation Surgery, Medical Faculty and University Hospital Magdeburg, Otto-von-Guericke University, Magdeburg, Germany.
Pancreatic cancer (PC) is a highly aggressive malignancy in humans, where early diagnosis significantly improves patient outcomes. However, effective methods for accurate and early detection remain limited. In this multiethnic study involving human subjects, we developed a liquid biopsy signature based on extracellular vesicle (EV)-derived microRNAs (miRNAs) linked to radiomics features extracted from patients' tumor imaging.
View Article and Find Full Text PDFGenes (Basel)
June 2025
Department of Medicine, Faculty of Medicine, Health and Sports, European University of Madrid, 28108 Madrid, Spain.
Stereotactic body radiotherapy (SBRT) delivers ablative radiation doses with sub-millimeter precision. Radiogenomic studies, meanwhile, provide insights into how tumor-intrinsic genetic factors influence responses to such high-dose treatments. This review explores the radiobiological mechanisms underpinning SBRT efficacy, emphasizing the roles of DNA damage response (DDR) pathways, tumor suppressor gene alterations, and inflammatory signaling in shaping tumor radiosensitivity or resistance.
View Article and Find Full Text PDF